Intravenous arketamine for treatment-resistant depression: open-label pilot study
European Archives of Psychiatry and Clinical Neuroscience February 20, 2020 Gustavo C. Leal, Igor D. Bandeira, Fernanda S. Correia-Melo et al. 257 citations
We aimed to analyze the efficacy and safety of arketamine, the R (−)-enantiomer of ketamine, for treatment-resistant depression (TRD) in humans. Open-label pilot trial, seven subjects with TRD received a single intravenous infusion of arketamine (0.5 mg/kg); primary outcome was change in Montgomery–Åsberg Depression Rating Scale (MADRS) 24 h after. Mean MADRS dropped from 30.7 before infusion...